Elypta proudly sponsors the first prospective multi-center clinical study in renal cell carcinoma diagnostics from the AURORAX series


AURORAX-087A (AUR87A) is a planned prospective multi-center observational clinical study to validate the clinical performance of Elypta’s platform in the early detection of recurrence after surgery in patients with high or intermediate risk clear cell renal cell carcinoma. Early detection of recurrence is crucial to improve the chances of survival of patients.

Key facts

  • Open for recruitment starting 2020

  • Sites open in the European Union and United States

  • Endorsed by European Association of Urology (EAU) Guidelines Panel for Renal Cell Carcinoma Chairman and Vice-Chairman

  • Endorsed by the International Kidney Cancer Coalition

If you are interested in the progress of AURORAX trials, follow us on LinkedIn!


This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 849251